ADIL earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -0.28. Updated 2026-07-23.
Adial Pharmaceuticals (ADIL) Research Hub
Adial Pharmaceuticals (ADIL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.9 USD (-17.37%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.28, market cap 0.00B. This hub links to the full technical, earnings and options research available for ADIL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.9 USD (-17.37%) |
| 52-week range | 2.33 USD – 7.2 USD |
| Trend regime | Range |
| 14-day RSI | 56.7 (Bullish) |
| Trailing P/E | -0.28 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ADIL
Covered Call on ADIL: how it works, illustrative setup around the real 4.9 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADIL: how it works, illustrative setup around the real 4.9 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADIL: how it works, illustrative setup around the real 4.9 USD price, max profit/loss, breakeven and when to use it. Educational.
ADIL technical analysis: range, last 4.9 USD, RSI 56.7, 52w range 2.33 USD–7.2 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ADIL in?
Adial Pharmaceuticals (ADIL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ADIL in an uptrend or downtrend?
As of 2026-09-11, ADIL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADIL's trailing P/E ratio?
ADIL's trailing P/E is -0.28, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ADIL next report earnings?
ADIL is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -1.01667 USD.